AURO-DIMETHYL FUMARATE CAPSULE (DELAYED RELEASE)
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
22-08-2023
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
DIMETHYL FUMARATE
Tilgjengelig fra:
AURO PHARMA INC
ATC-kode:
L04AX07
INN (International Name):
DIMETHYL FUMARATE
Dosering :
120MG
Legemiddelform:
CAPSULE (DELAYED RELEASE)
Sammensetning:
DIMETHYL FUMARATE 120MG
Administreringsrute:
ORAL
Enheter i pakken:
100
Resept typen:
Prescription
Produkt oppsummering:
Active ingredient group (AIG) number: 0154210001; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2023-08-28
Preparatomtale
AURO-DIMETHYL FUMARATE (Dimethyl Fumarate Delayed-Release Capsules)
Page 1 of 43
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
AURO-DIMETHYL FUMARATE
Dimethyl Fumarate Delayed-Release Capsules
Delayed-Release Capsules, 120 mg and 240 mg, Oral
House Standard
Antineoplastic and Immunomodulating Agents
Auro Pharma Inc.
3700 Steeles Avenue West, Suite # 402
Woodbridge, Ontario, L4L 8K8
Canada
Date of Initial Authorization:
August 22, 2023
Submission Control Number: 269223
AURO-DIMETHYL FUMARATE (Dimethyl Fumarate Delayed-Release Capsules)
Page 2 of 43
RECENT MAJOR LABEL CHANGES
Not Applicable
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES.........................................................................................
2 TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1 INDICATIONS
......................................................................................................................
4
1.1 Pediatrics
.......................................................................................................................
4
1.2
Geriatrics........................................................................................................................
4
2 CONTRAINDICATIONS
.........................................................................................................
4
4 DOSAGE AND ADMINISTRATION
........................................................................................
4
4.1 Dosing Considerations
...................................................................................................
4
4.2 Recommended Dose and Dosage Adjustment
............................................................... 5
4.4 Administration
......................................................
Les hele dokumentet
